Audentes Therapeutics Inc (BOLD) Downgraded by Zacks Investment Research to Sell
Audentes Therapeutics Inc (NASDAQ:BOLD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
A number of other brokerages also recently weighed in on BOLD. Piper Jaffray Cos. set a $24.00 price objective on Audentes Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 31st. Cowen and Company began coverage on Audentes Therapeutics in a report on Monday, August 15th. They set an “outperform” rating on the stock. Finally, Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Audentes Therapeutics in a report on Thursday, September 1st.
Audentes Therapeutics (NASDAQ:BOLD) traded up 1.53% during midday trading on Wednesday, hitting $19.25. 40,026 shares of the company traded hands. Audentes Therapeutics has a 12-month low of $13.06 and a 12-month high of $20.42. The stock has a 50 day moving average price of $15.91 and a 200-day moving average price of $15.51. The company’s market cap is $418.21 million.
In other Audentes Therapeutics news, major shareholder Versant Ventures Iv, Llc bought 35,000 shares of the company’s stock in a transaction dated Monday, July 25th. The shares were bought at an average price of $15.00 per share, for a total transaction of $525,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James E. Flynn bought 400,000 shares of the company’s stock in a transaction dated Monday, July 25th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $6,000,000.00. The disclosure for this purchase can be found here.
About Audentes Therapeutics
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Stock Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related stocks with our FREE daily email newsletter.